|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results confirm that PATZ1 downregulation has a critical role in thyroid carcinogenesis, showing that it cooperates with RET/PTC1 in thyroid cancer progression.
|
29584698 |
2018 |
|
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
By RT-PCR we evaluated the relative levels of 15 microRNAs (miR-221, -222, -146b, -181b, -21, -187, -199b, -144, -192, -200a, -200b, -205, -141, -31, -375) and the presence of BRAF(V600E) mutation and RET-PTC1 translocation in surgically resected lesions from 208 patients from Novosibirsk oblast (Russia) with different types of thyroid neoplasms.
|
26960768 |
2016 |
|
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We evaluated the best tagging SNPs from our previous PTC study and additionally included SNPs in or near FOXE1 and NKX2-1 genes, known susceptibility loci for thyroid cancer.
|
27207655 |
2016 |
|
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Of 265 TC, 34 (12.8%) harbored TERT promoter mutations, including 10/153 (6.5%) conventional papillary TC (CPTC), 8/57 (14.0%) follicular variant PTC, 9/30 (30%) tall cell variant PTC, 1/3 (30%) Hurthle cell thyroid cancer (HTC), 1/5 (20%) follicular TC, and 5/13 (38.5%) poorly differentiated TC.
|
26354077 |
2015 |
|
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF(V600E) mutation analysis is superior to RAS point mutations and evaluation of RET/PTC rearrangements in the diagnosis of thyroid cancer, even in indeterminate lesions.
|
25333496 |
2015 |
|
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thyroid cancer (TC) is frequently associated with BRAF or RAS oncogenic mutations and RET/PTC rearrangements, with aberrant RAF-MEK-ERK and/or PI3K pathway activation.
|
26265449 |
2015 |
|
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Twenty-four (27%) of 89 patients were diagnosed with thyroid cancer (50% papillary thyroid carcinoma [PTC], 50% follicular variant of papillary thyroid carcinoma [FVPTC]).
|
25627462 |
2015 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
The posttest probability of thyroid cancer was 100% for nodules positive for BRAF or RET-PTC, 70% for RAS or PAX8-PPARG, and 88% for molecular cytology overall.
|
24811481 |
2014 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, expression of Sin1 and activation of AKT kinase were analyzed in fresh-frozen tissue samples (normal/tumor), primary cell cultures (papillary thyroid carcinoma [PTC]), and an established thyroid cancer cell line (medullary thyroid carcinoma) by Western blotting.
|
25456951 |
2014 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
We did a comprehensive screen for 548 known and putative fusion genes in 27 samples of thyroid tumors and three positive controls-one thyroid cancer cell line (TPC-1) and two PTCs with known CCDC6-RET (alias RET/PTC1) fusion gene, using this microarray.
|
22961909 |
2012 |
|
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
RET/PTC is a characteristic genetic alteration frequently found in radiation-induced thyroid cancer in human populations.
|
22136268 |
2011 |
|
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Common mutations found in thyroid cancer are point mutation of the BRAF and RAS genes as well as RET/PTC and PAX8/PPARγ chromosomal rearrangements.
|
21878896 |
2011 |
|
Thyroid Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Three archival thyroid cancer tissue specimens from three different patients were used as in-house controls to determine the conditions for an improved switching mechanism at 5' end of RNA transcript (SMART) RACE method; one tissue specimen with RET/PTC1 rearrangement and one with RET/PTC3 rearrangement were used as positive samples.
|
19785523 |
2010 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several types of rearrangement known to occur in thyroid cancer, including RET/PTC, NTRK1 and BRAF/AKAP9, are more common in radiation-associated thyroid tumors and RET/PTC can be induced experimentally by exposing human thyroid cells to ionizing radiation.
|
19766698 |
2010 |
|
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The molecular pathology of thyroid cancer is now better understood because of our ability to identify RET/PTC rearrangements and BRAF mutations in the aetiopathogenesis of the large majority of PTCs and the high prevalence of RAS mutations and PAX8/PPARgamma rearrangements in follicular patterned carcinomas (FTCs and follicular variant of PTCs).
|
19147628 |
2009 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Even though RET/PTC is a specific genetic event in the carcinomas, our results suggested the possibility of RET/PTC as "passenger" abnormalities rather than "driver" oncogenic mutation during thyroid cancer progression, warranting further studies on mechanisms and implication of RET gene instability.
|
19495791 |
2009 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hashimoto Thyroiditis (H.T.) is a destructive autoimmune thyroid condition whose precise molecular pathogenesis remains unclear. ret/PTC-1 is a chimeric transcript which has been described in autoimmune thyroid disease (AITD) and thyroid neoplasia.
|
18505566 |
2008 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Oncogenic proteins such as Ret/PTC, Ras and BRAF can induce NF-kappaB activation making it an important change in thyroid cancer.
|
17891249 |
2007 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
In fact, it has been demonstrated that: a) RET/PTC is an early event in the process of thyroid carcinogenesis and has a critical role in the generation of the papillary carcinoma; b) RET/PTC activation is essentially restricted to the papillary histotype and to the Hürthle thyroid tumors; c) its incidence increases after exposure to radiations.
|
17891236 |
2007 |
|
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
H4(D10S170) gene has been identified upon its frequent rearrangement with RET in papillary thyroid tumours (RET/PTC1).
|
17420723 |
2007 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed the methylation pattern of 17 gene promoters in nine thyroid cancer cell lines and in 38 primary thyroid carcinomas (13 papillary thyroid carcinoma [PTC], 10 follicular thyroid carcinoma [FTC], 9 undifferentiated thyroid carcinoma [UTC], 6 medullary thyroid carcinoma [MTC]), 12 goiters, and 10 follicular adenomas (FA) by methylation- specific polymerase chain reaction (PCR).
|
16889486 |
2006 |
|
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we use an 18 Mb region on 10q11.2-21 containing the RET gene and its recombination partners, the H4 and NCOA4 (ELE1) genes, as a model chromosomal region frequently involved in RET/PTC rearrangements in thyroid cancer.
|
16331264 |
2006 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study we analyzed the prevalence of ret/PTC1 and ret/PTC3 in thyroid tumors from 21 liquidators, 31 nonirradiated adult Ukrainian patients, and 34 nonirradiated adult French patients. ret rearrangements in carcinomas were found in 83.3% of liquidators, 64.7% of Ukrainian patients, and 42.9% of French patients.
|
15788648 |
2005 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical technique is proved to be a useful tool to detect RFT/PTC activation in thyroid tumors.
|
15368067 |
2005 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
The authors investigated the prevalence of RET/PTC in a large number of thyroid tumors from Japanese patients.
|
16015630 |
2005 |